NASDAQ: PTNPalatin Technologies Inc Stock
$6.02-0.47 (-7.24%)
Updated Oct 16, 2026
PTN Price
$6.02
Fair Value Price
N/A
Market Cap
$10.72M
52 Week Low
$5.61
52 Week High
$31.00
P/E
-2.03x
P/B
1.6x
P/S
2.31x
PEG
N/A
Dividend Yield
N/A
Revenue
$13.19M
Earnings
-$8.38M
Gross Margin
100%
Operating Margin
-63.49%
Profit Margin
-63.5%
Debt to Equity
0.28
Operating Cash Flow
-$14M
Beta
1.12
Next Earnings
Nov 13, 2026
Ex-Dividend
N/A
Next Dividend
N/A
PTN Overview
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PTN's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
PTN
Ranked#250 of 455
Ranked#250 of 455
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.83 | A | |
| $121.84 | A | |
| $9.98 | A |
Be the first to know about important PTN news, forecast changes, insider trades & much more!
PTN News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PTN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PTN is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PTN is good value based on its book value relative to its share price (1.6x), compared to the US Biotechnology industry average (4.89x)
P/B vs Industry Valuation
PTN is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more PTN due diligence checks available for Premium users.
Valuation
PTN fair value
Fair Value of PTN stock based on Discounted Cash Flow (DCF)
Price
$6.02
Fair Value
$4.46
Overvalued by
35.01%
PTN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PTN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.03x
Industry
18.7x
Market
42.68x
PTN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.6x
Industry
4.89x
PTN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PTN's financial health
Profit margin
Revenue
$300.8k
Net Income
-$4.4M
Profit Margin
-1,449.1%
PTN's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
PTN's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$8.5M
Liabilities
$1.8M
Debt to equity
0.28
PTN's short-term assets ($8.16M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PTN's short-term assets ($8.16M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PTN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PTN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.7M
Investing
$0.0
Financing
$22.5k
PTN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PTN vs Biotech Stocks
Palatin Technologies Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.